Transgene S.A.
TNG.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | 0.19 | -0.10 | 0.00 |
| FCF Yield | -33.56% | -26.91% | -13.24% | -14.10% |
| EV / EBITDA | -2.74 | -4.38 | -5.78 | -9.74 |
| Quality | ||||
| ROIC | -125.68% | -82.30% | -54.53% | -27.17% |
| Gross Margin | -439.56% | -274.53% | -929.05% | -229.06% |
| Cash Conversion Ratio | 0.69 | 1.55 | 0.62 | 1.64 |
| Growth | ||||
| Revenue 3-Year CAGR | 26.67% | -7.54% | 1.60% | -9.08% |
| Free Cash Flow Growth | 28.85% | -71.34% | 33.07% | -10.26% |
| Safety | ||||
| Net Debt / EBITDA | 0.24 | 0.51 | 0.07 | 0.09 |
| Interest Coverage | -21.21 | 0.00 | -37.19 | -50.70 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 2.01 | 0.00 |
| Cash Conversion Cycle | -33.02 | -14.16 | 444.94 | -85.38 |